WCLC 2022 | Molecular testing in EGFR mutant driven NSCLC

Julia Rotow, MD, Dana-Farber Cancer Institute, Boston, MA, discusses molecular testing for EGFR mutations in lung cancer in both the metastatic and early-stage settings. Cell-free DNA (cfDNA) is a useful supplement to biomarker testing and is most practical in the metastatic setting due to the levels of cfDNA being highest in more advanced disease. However, with technology improving, cfDNA will likely play a role in all stages of biomarker testing in the future. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.